Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 84,030 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: therapy Clear all

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Influenza
Interventions: Baloxavir Marboxil, Oseltamivir; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib, Tislelizumab, ctDNA
Interventions: Tislelizumab, Fruquintinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Traumatic Brain Injury
Interventions: Autologous HB-adMSCs, Normal Saline; Biological · Drug
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Opioid-use Disorder, Medication Assisted Treatment, Chronic Pain
Interventions: Psychosocial Pain Management (PPMI), Enhanced Usual Care (EUC); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Alzheimer's Disease, Dementia, Behavioral Symptoms
Interventions: Divalproex ER, Quetiapine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 55 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Interventions: SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice; Biological · Drug
Lead sponsor: BriaCell Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 79
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more

Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: ixabepilone, bevacizumab; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Depression
Interventions: Computer-based Problem-Solving Treatment; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 30 Years to 60 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Neoplasm
Interventions: fluorine F 18 d-FMAU, positron emission tomography, computed tomography; Radiation · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 19 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Kidney Failure, Chronic
Interventions: Alendronate, Teriparatide, Cinacalcet; Drug
Lead sponsor: Hartmut Malluche, MD; Other
Eligibility: 21 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Dry Eye
Interventions: Rimexolone; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: AEVI-001, Placebo; Drug
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Wayne, Pennsylvania

Conditions: Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
Interventions: imiquimod, fluorouracil, infrared photocoagulation therapy, thermal ablation therapy, laser therapy, clinical observation, laboratory biomarker analysis; Drug · Device · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 35 Years and older
Enrollment: 4,446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 24
States / cities: Los Angeles, California • Palm Springs, California • San Francisco, California + 13 more

Conditions: Disruptive Behavior, Attention-deficit Hyperactivity, Oppositional Defiant Disorder
Interventions: Garmin; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Thoracolumbar Spine Trauma
Interventions: Percutaneous Pedicle Screw Fixation, Open Treatment; Procedure
Lead sponsor: Daniel Altman; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prediabetes / Type 2 Diabetes
Interventions: Metformin, GLP-1A, MED; Drug · Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Endometriosis
Interventions: Real stimulation VS Sham; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 64 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COPD, Interstitial Lung Disease
Interventions: Cell therapy; Procedure
Lead sponsor: Lung Institute; Industry
Eligibility: 16 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Help-Seeking Behavior, Stigma, Social
Interventions: NAMI Mental Health 101 and NAMI FaithNet; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 1,713 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia
Interventions: tipifarnib, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain and Central Nervous System Tumors
Interventions: cintredekin besudotox, adjuvant therapy, conventional surgery, neoadjuvant therapy; Biological · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: Oxytocin, Inactive placebo nasal spray; Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Seasonal Allergic Rhinitis
Interventions: Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 12 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Fort Worth, Texas

Search by objective public record fields.

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Self-guided Depression Treatment on Long-duration Spaceflights: A Continuation Study

18F-FMAU PET/CT in Imaging Patients With Advanced Cancers

Renal Osteodystrophy: An Individual Management Approach

Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Monitoring of Sleep and Behavior of Children 3-7 Years Old Receiving Parent-Child Interaction Therapy With the Help of Artificial Intelligence

Treatment of Thoracolumbar Spine Fractures: Percutaneously Placed Pedicle Screws Versus Open Treatment

Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

Ear Electro-stimulation for Chronic Pelvic Pain

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Autologous Stem Cell Treatment for Chronic Lung Disease Study

Delivering Church-based Interventions to Reduce Stigma and Mental Health Treatment Disparities Among Latinos

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma

Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid